Or call
(888) 352-RUSH for help arranging an appointment.
Specialty:
Board Certification:
Faculty Rank: Professor
Medical or Graduate Education:
New Jersey Medical School
Residency:
Massachusetts General Hospital - Psychiatry
Fellowship:
Massachusetts General Hospital - Psychiatry
Clinical Expertise:
Addiction treatment
Anxiety disorders
Bipolar disorder
Depressive disorders
Mood disorders
Obsessive-compulsive disorder
Panic disorder
Phobias
Post-traumatic stress disorder
Psychopharmacology
Psychopharmacology integrated with medical management
Psychotropic medication management
Stress-related disorders
Traumatic stress
Research Interests:
Acute and long-term course and treatment of anxiety and traumatic stress disorders
Development of novel therapuetics for mood and anxiety disorders
Combined cognitive-behavioral and pharmacotherapy for anxiety disorders
Treatment refractory mood and anxiety disorders
Pathophysiology and treatment of substance abuse
Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.
Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity. D-Cycloserine Enhancement of Fear Extinction is Specific to Successful Exposure Sessions: Evidence from the Treatment of Height Phobia. Predictors of dropout from psychosocial treatment in opioid-dependent outpatients. Augmentation of exposure therapy with post-session administration of d-cycloserine. Loving-Kindness Meditation practice associated with longer telomeres in women. d-Cycloserine as an Augmentation Strategy With Cognitive-Behavioral Therapy for Social Anxiety Disorder. Predicting Treatment Response in Social Anxiety Disorder From Functional Magnetic Resonance Imaging. Plasma oxytocin immunoreactive products and response to trust in patients with social anxiety disorder. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. Anchoring the Panic Disorder Severity Scale. Sexual HIV risk behaviors in a treatment-refractory opioid-dependent sample. Avoidant personality disorder in individuals with generalized social anxiety disorder: what does it add? Mood regulation and quality of life in social anxiety disorder: an examination of generalized expectancies for negative mood regulation. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. Treatment change of somatic symptoms and cultural syndromes among Cambodian refugees with PTSD. The role of anxiety sensitivity in sleep disturbance in panic disorder. Understanding the relationship of perceived social support to post-trauma cognitions and posttraumatic stress disorder. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. Effect of Acute Posttrauma Propranolol on PTSD Outcome and Physiological Responses During Script-Driven Imagery. Culturally adapted CBT (CA-CBT) for Latino women with treatment-resistant PTSD: a pilot study comparing CA-CBT to applied muscle relaxation. RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. Khyâl attacks: a key idiom of distress among traumatized Cambodia refugees. Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation. Open-label support for duloxetine for the treatment of panic disorder. A comparison of emotional approach coping (EAC) between individuals with anxiety disorders and nonanxious controls. Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. Anger, PTSD, and the nuclear family: a study of Cambodian refugees. Nightmares among Cambodian refugees: the breaching of concentric ontological security. A PET study of tiagabine treatment implicates ventral medial prefrontal cortex in generalized social anxiety disorder. Anxiety disorder presentations in Asian populations: a review. Introduction to the special issue: anxiety disorders in cross-cultural perspective. A model of the generation of ataque de nervios: the role of fear of negative affect and fear of arousal symptoms. Mechanisms of efficacy of CBT for Cambodian refugees with PTSD: improvement in emotion regulation and orthostatic blood pressure response. Brain GABA levels in patients with bipolar disorder. Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. Childhood maltreatment linked to greater symptom severity and poorer quality of life and function in social anxiety disorder. Refractory generalized anxiety disorder. Redefining affective disorders: relevance for drug development. Changing times at CNS Neuroscience & Therapeutics. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. Anxiety is associated with impulsivity in bipolar disorder. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. The 'multiplex model' of somatic symptoms: application to tinnitus among traumatized Cambodian refugees. Oxytocin levels in social anxiety disorder. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam. A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Novel treatment approaches for refractory anxiety disorders. Ataque de nervios: relationship to anxiety sensitivity and dissociation predisposition. Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy. The panic attack-posttraumatic stress disorder model: applicability to orthostatic panic among Cambodian refugees. A functional MRI study of amygdala responses to angry schematic faces in social anxiety disorder.
To watch a brief video of Mark H. Pollack, MD, click the play button at the lower left corner of the video frame below. (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
View Transcript We’re able to offer people with mood, anxiety, substance abuse difficulties a whole array of effective kinds of treatments: pharmacologic treatments, medications and different kinds of talking therapies — either specific talking therapies that help people deal with some of the symptoms associated with their difficulties, or more general more open-ended kinds of therapies that may help them understand how they got to where they are now, and what they can do in the future to get better.
There’s been a lot of stigma, especially in the past, associated with psychiatric disorders. As we learn more about these difficulties we realize that they’re just another type of illness or difficulty that people have in the same way they may have heart disease, or lung disease or GI [gastrointestinal] disease.
I think the important thing to realize is that there’s always hope, that we keep working with people until they’re doing better, and most of our patients do, in fact, experience a significant improvement in the quality of their life.
;){kind=link}
;){kind=link}